Does Current Scientific and Clinical Evidence Support the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Premature Ejaculation? A Systematic Review and Meta‐analysis

摘要: ABSTRACT Introduction Premature ejaculation (PE) is a highly prevalent and complex syndrome that remains poorly defined inadequately characterized. Pharmacotherapy represents the current basis of lifelong PE treatment. Aim The goal this study was to assess role phosphodiesterase type 5 inhibitors (PDE5‐Is) in treatment patients with without associated erectile dysfunction (ED). Main Outcome Measure posttreatment intravaginal ejaculatory latency time used as primary end point efficacy. Methods A systematic review literature performed by electronically searching MedLine database for peer‐reviewed articles regarding mechanism action clinical trials PDE5 management PE. meta‐analysis these studies pool Results Twenty‐nine examined supposed mechanisms 14 reported data from were reviewed. may exert their influence increasing levels nitric oxide both centrally (reducing sympathetic drive) peripherally (leading smooth‐muscle dilatation seminal tract). These drugs also induce peripheral analgesia prolong duration erection, increase confidence, improve perception control overall sexual satisfaction, decrease postorgasmic refractory achieving second erection after ejaculation. Concerning efficacy, shows an positive effect use monotherapy or components combination regimen major limitations published included poor design, absence solid methodology, which characterized lack unique definition, appropriate endpoints outcome evaluation placebo arm Institutional Review Board approval. Conclusion There inadequate, partial basic, evidence support Asimakopoulos AD, Miano R, Agro EF, Vespasiani G, Spera E. Does scientific premature ejaculation? meta‐analysis. J Sex Med 2012;9:2404–2416.